Proqr Therapeutics N.V. balance sheet

At the end of fiscal 2025, Proqr Therapeutics N.V. had total assets of $132m, total liabilities of $74.4m and shareholders' equity of $57.9m. It held $108m in cash against $5.7m of debt: net cash of $103m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Proqr Therapeutics N.V.: balance sheet, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	212	101	132	155	108
Receivables	—	—	—	4	8
Total current assets	217	165	134	159	118
Total assets	237	183	153	174	132
Total current liabilities	31	22	38	40	38
Short-term debt	5	—	—	—	—
Long-term debt	45	5	5	—	—
Total debt	50	7	5	5	6
Total liabilities	109	112	107	82	74
Shareholders' equity	129	72	46	92	58
Net debt (negative = net cash)	−162	−94	−127	−150	−103

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CTMX vs PRQR CELU vs PRQR PRQR vs SCYX KROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Proqr Therapeutics N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Proqr Therapeutics N.V.